Results 21 to 30 of about 280,195 (357)

Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year followup in the West of Scotland Cancer Network [PDF]

, 2011
Clinically and biologically, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has much more in common with germinal-center derived B-cell non-Hodgkin lymphoma (NHL) than with classical Hodgkin lymphoma (cHL).
Diehl V, Fanale MA, Hasenclever D, Katrina Farrell, Mike Leach, Orlandi E, Pamela Mckay, Savage KJ, Stein H   +8 more
core   +1 more source

Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.

New England Journal of Medicine, 2020
BACKGROUND Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin's lymphoma are limited.
V. Minard-Colin, A. Aupérin, M. Pillon, G. Burke, D. Barkauskas, K. Wheatley, Rafael F Delgado, S. Alexander, A. Uyttebroeck, C. Bollard, J. Zsiros, M. Csóka, B. Kazanowska, A. Chiang, R. Miles, A. Wotherspoon, P. Adamson, G. Vassal, C. Patte, T. Gross   +19 more
semanticscholar   +1 more source

Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols

Haematologica, 2017
Mature B-cell non-Hodgkin lymphoma is the most common subtype of non-Hodgkin lymphoma in childhood and adolescence. B-cell non-Hodgkin lymphomas are further classified into histological subtypes, with Burkitt lymphoma and Diffuse large B-cell lymphoma ...
Marius Rohde, Bettina R. Bonn, Martin Zimmermann, Jonas Lange, Anja Möricke, Wolfram Klapper, Ilske Oschlies, Monika Szczepanowski, Inga Nagel, Martin Schrappe, MMML-MYC-SYS Project, ICGC MMML-Seq Project, Markus Loeffler, Reiner Siebert, Alfred Reiter, Birgit Burkhardt   +15 more
doaj   +1 more source

Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases [PDF]

, 1995
The authors describe one case of a rare primitive non-Hodgkin lymphoma of the uterus, and two cases of primary non-Hodgkin lymphoma of the breast. Histologically, the uterine lymphoma, although clinically confined to the uterus, was a diffuse large cell ...
Amato, C., CIPOLLA, Calogero, GEBBIA, Nicolo', GEBBIA, Vittorio, Lampasona, G., Latteri, M.   +5 more
core   +1 more source

Primary Non-Hodgkin Lymphoma of The Cervix [PDF]

International Journal of Hematology-Oncology and Stem Cell Research, 2011
Background: There are only a few reports that exist regarding primary non-Hodgkin lymphoma of the genital tract. In this article, one case of primary B-cell type non-Hodgkin lymphoma (NHL) of the cervix is presented.
Nasim Valizadeh, Haleh Ayatollahi, Siamak Naji   +2 more
doaj   +1 more source

Non-Hodgkin's lymphoma: A review

Journal of Family Medicine and Primary Care, 2020
Lymphomas constitute the third most common neoplasm in head and neck region arising from the lymphoreticular system. Malignant lymphomas are divided into Hodgkin's disease and non-Hodgkin's lymphoma (NHL).
Rohit Singh, S. Shaik, B. Negi, J. Rajguru, Pankaj Patil, Dr. Anuj S. Parihar, Uma Sharma   +6 more
semanticscholar   +1 more source

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]

, 2016
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S., Fanale, Michelle A., Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S., Janku, Filip, Kaseb, Ahmed O., Kurzrock, Razelle, Meric-Bernstam, Funda, Naing, Aung, Park, Haeseong, Patel, Shreyaskumar, Piha-Paul, Sarina A., Subbiah, Vivek, Tsimberidou, Apostolia M., Velez-Bravo, Vivianne M M., Wheler, Jennifer J., Zinner, Ralph G.   +17 more
core   +2 more sources

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.

Journal of Clinical Oncology, 2019
PURPOSE Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies.
I. Flinn, Carole B. Miller, K. Ardeshna, S. Tetreault, S. Assouline, J. Mayer, M. Merli, S. Lunin, A. Pettitt, Z. Nagy, O. Tournilhac, K. Abou-Nassar, M. Crump, E. Jacobsen, S. de Vos, V. Kelly, Weiliang Shi, L. Steelman, N. Le, D. Weaver, S. Lustgarten, N. Wagner-Johnston, P. Zinzani   +22 more
semanticscholar   +1 more source

Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper [PDF]

, 2016
Objectives: In this paper, we present a review of critical concepts and research perspectives and produce recommendations on the optimal use of pixantrone in non-Hodgkin lymphoma (NHL) by group discussion from an expert panel appointed by the Italian ...
Barosi, Giovanni, Corradini, Paolo, Martelli, Maurizio, Minotti, Giorgio, Oliva, Stefano, Spina, Michele, Tura, Sante, Zinzani, Pier Luigi   +7 more
core   +1 more source

Association of group erythrocyte antigens and B-cell non-Hodgkin lymphoma

Regulatory Mechanisms in Biosystems, 2016
We analyzed the frequency distribution of blood groups AB0, Rhesus and Kell in patients with B-cell non-Hodgkin lymphoma. An increase of D− patients (31.0%) among ill in comparison to healthy individuals (16.5%) was found.
U. V. Tymoshenko, S. O. Sivkovych, K. G. Garkava, R. P. Pavlyuk, G. A. Myronenko   +4 more
doaj   +1 more source